Glechoma Hederacea Flowering Top

Dosage for Glechoma Hederacea Flowering Top is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels.

Diagnostic Testing

• Skin Prick Test (SPT): One drop of the extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a superficial puncture. Results are read after 15–20 minutes.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, 0.02 mL of a 1:100 or 1:1000 dilution may be injected into the dermis.

Immunotherapy (SCIT)

• Build-up Phase: Initial doses often start as low as 0.05 mL of a highly dilute solution (e.g., 1:100,000 w/v). Doses are increased weekly or bi-weekly by 50% to 100% until a maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose is achieved (often 0.5 mL of a 1:100 or 1:10 w/v concentration), injections are spaced out to every 2–4 weeks.

Pediatric dosing follows the same principles as adult dosing but requires extreme caution. Children as young as 2 years old may undergo skin testing, though some clinicians prefer to wait until age 5 for immunotherapy due to the child's ability to communicate symptoms of a systemic reaction. The volume of the injection remains similar to adult doses, but the starting concentration may be more conservative in highly atopic children.

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the extract is not cleared through the kidneys in a manner that affects systemic toxicity. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus), which can interfere with test interpretation.

Hepatic Impairment

No adjustments are necessary for patients with liver disease, as hepatic metabolism is not a primary route of clearance for allergenic proteins.

Elderly Patients

Elderly patients may have reduced skin turgor and decreased histamine response, potentially leading to false-negative skin tests. Careful observation for cardiovascular stress during immunotherapy is required in this population.

This product is never for self-administration or oral use. It must be administered by a healthcare professional.

• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
• Administration: For immunotherapy, the injection is given subcutaneously, usually in the posterior aspect of the upper arm. The site should be rotated between the left and right arms.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following any injection to monitor for anaphylaxis.

In immunotherapy, if a dose is missed:

• < 1 week late: Continue with the scheduled dose.
• 1–2 weeks late: The dose may need to be reduced to the previous level.
• > 4 weeks late: The entire build-up process may need to be restarted from a lower concentration to ensure safety.

An overdose of allergenic extract usually manifests as an immediate, severe systemic reaction.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines. Seek emergency medical services immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequent side effects associated with Glechoma Hederacea Flowering Top are localized to the site of administration. These are often expected as part of the diagnostic or therapeutic process.

• Local Wheal and Flare: A small, itchy bump (wheal) surrounded by redness (flare) at the test site. This typically peaks at 20 minutes and resolves within 2 hours.
• Injection Site Swelling: In immunotherapy, swelling up to the size of a half-dollar (approx. 3-5 cm) is common. It may feel warm, itchy, or slightly tender.
• Pruritus (Itching): Intense itching at the site of the skin test or injection.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm at the injection site. This may persist for 24–48 hours and can be managed with cold compresses and oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild tension-type headaches have been reported following allergen exposure during testing.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Vasovagal Reaction: Fainting or lightheadedness, often triggered by the needle stick rather than the extract itself.

> Warning: Stop taking Glechoma Hederacea Flowering Top and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening systemic allergic reaction. Symptoms include a feeling of impending doom, rapid pulse, difficulty breathing, and a sharp drop in blood pressure.
• Bronchospasm: Sudden constriction of the airways, leading to severe wheezing and shortness of breath, particularly in patients with pre-existing asthma.
• Laryngeal Edema: Swelling of the throat or larynx that can obstruct the airway, characterized by a hoarse voice or difficulty swallowing.
• Hypotension: A dangerous drop in blood pressure that may cause dizziness or fainting.

There are no known long-term 'toxic' effects of Glechoma Hederacea Flowering Top, as it is a biological protein extract. However, prolonged immunotherapy can lead to 'immunological memory,' which is the intended therapeutic effect. In rare cases, persistent nodules (granulomas) may form at the injection site if the extract is injected too superficially or if the patient reacts to the glycerin or aluminum salts (if present in the adjuvant).

While Glechoma Hederacea Flowering Top may not have a specific named 'Black Box' in the same way as synthetic drugs, all allergenic extracts carry a strict FDA-mandated warning regarding Anaphylaxis.

Summary of Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It must only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and who are prepared to manage emergencies. Patients with unstable asthma are at a significantly higher risk for fatal reactions. All patients must be observed for a minimum of 30 minutes post-administration.

Report any unusual symptoms to your healthcare provider.

Glechoma Hederacea Flowering Top is intended solely for use by healthcare professionals trained in allergy management. It is not for home use. The most critical safety consideration is the potential for a systemic allergic reaction, which can occur even in patients who have previously tolerated the extract without issue.

No specific FDA black box warning exists specifically for the Glechoma species, but the entire class of Non-Standardized Allergenic Extracts carries a general warning for risk of severe systemic reactions. The warning emphasizes that the extract should be used with extreme caution in patients with severe or poorly controlled asthma, as these individuals are at the highest risk for a fatal outcome if a reaction occurs.

• Anaphylaxis Risk: The risk of anaphylaxis is always present. Healthcare facilities must have 'crash carts' equipped with epinephrine, oxygen, antihistamines, and airway management tools.
• Asthma Stability: Patients experiencing an asthma flare-up or who have a reduced Peak Expiratory Flow (PEF) should not receive immunotherapy injections until their asthma is stabilized.
• Cardiovascular Disease: Patients with significant heart disease may be less able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine if it is required.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) are at a higher risk because these drugs can interfere with the effectiveness of epinephrine used during an emergency.

• Pre-Injection Assessment: The clinician should assess the patient for current allergy symptoms, asthma stability, and any new medications.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is required.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after the injection to ensure no significant bronchoconstriction has occurred.
• Skin Test Interpretation: Accurate measurement of the wheal and flare diameter is essential to avoid over-dosage.

Most patients can drive or operate machinery after the 30-minute observation period. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive and should be monitored in an emergency department.

Alcohol consumption should be avoided for several hours before and after an allergy injection. Alcohol can increase peripheral vasodilation, which may potentially accelerate the absorption of the allergen or exacerbate a systemic reaction.

Discontinuation of immunotherapy should be discussed with a doctor. Abruptly stopping immunotherapy does not cause 'withdrawal' symptoms, but it will result in the loss of the immunological tolerance built up during treatment, leading to a return of allergy symptoms.

> Important: Discuss all your medical conditions with your healthcare provider before starting Glechoma Hederacea Flowering Top.

There are no absolute drug-drug contraindications that prevent the use of Glechoma Hederacea Flowering Top, but certain combinations significantly increase the risk of a fatal outcome during a reaction:

• Beta-Blockers and Epinephrine: While not strictly contraindicated for the extract itself, the use of beta-blockers makes the treatment of a potential reaction (with epinephrine) much more difficult. This is a high-risk combination that requires a careful risk-benefit analysis.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (e.g., lisinopril) may experience more severe or frequent systemic reactions to allergenic extracts.
• MAO Inhibitors (MAOIs): Drugs like phenelzine can potentiate the effects of sympathomimetic amines, potentially complicating the management of a reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can interfere with the body's response to emergency medications.

• Antihistamines (H1 Blockers): Drugs like cetirizine, loratadine, and diphenhydramine will suppress the skin's response to the extract. These must be discontinued for 3 to 7 days before skin testing to avoid false-negative results.
• H2 Blockers: Medications like famotidine may also mildly suppress skin test reactivity and should be stopped 48 hours prior to testing.
• Topical Steroids: Applying steroid creams to the test site can suppress the local inflammatory response and should be avoided for at least one week.

There are no direct food interactions with Glechoma Hederacea Flowering Top. However, patients with a 'Mint family' allergy should be cautious of cross-reactive foods such as peppermint, oregano, and basil, as consuming these shortly before testing might increase the baseline level of immune activation.

• St. John's Wort: May affect the metabolism of other medications but has no known direct interaction with allergenic extracts.
• High-dose Vitamin C: Some evidence suggests very high doses of Vitamin C may have a mild antihistamine effect, potentially interfering with skin test accuracy.

• Skin Testing: The extract itself is the 'test.' The primary interaction is with any drug that suppresses the histamine response.
• Serum IgE Tests: The administration of the extract does not typically interfere with in vitro (blood) tests for specific IgE, such as RAST or ImmunoCAP.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug) rather than pharmacokinetic (affecting the drug's levels in the blood).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Glechoma Hederacea Flowering Top must NEVER be used in the following circumstances:

• Previous Severe Anaphylaxis: If a patient has had a near-fatal reaction to Glechoma hederacea extract in the past, further use is contraindicated.
• Severe, Uncontrolled Asthma: Patients whose asthma is not well-managed with standard therapy (e.g., FEV1 consistently below 70% of predicted) are at an unacceptable risk for fatal bronchospasm.
• Acute Infection: Testing or injections should be postponed if the patient has an active fever or respiratory infection, as this can lower the threshold for a systemic reaction.

These conditions require a careful risk-benefit analysis by the allergist:

• Autoimmune Diseases: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to immunotherapy.
• Malignancy: Patients undergoing active chemotherapy or radiation may have compromised immune systems that make immunotherapy less effective or more risky.
• Recent Myocardial Infarction: The stress of a potential systemic reaction could trigger a secondary cardiac event in patients with unstable heart disease.

Patients who are allergic to other members of the Lamiaceae family may show cross-sensitivity to Glechoma Hederacea Flowering Top. This includes:

• Mentha (Mint)
• Salvia (Sage)
• Thymus (Thyme)
• Nepeta (Catnip)

If a patient has had a severe reaction to any of these related plants, the initial dose of Glechoma extract should be significantly reduced.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Glechoma Hederacea Flowering Top.

Glechoma Hederacea Flowering Top is generally classified as Pregnancy Category C.

• Diagnostic Testing: It is generally recommended to defer skin testing until after delivery to avoid the risk of a systemic reaction, which could cause uterine contractions or fetal hypoxia.
• Immunotherapy: Most allergists will not start a new course of immunotherapy during pregnancy. However, if a patient is already on a stable maintenance dose and is tolerating it well, the treatment may be continued at the same or a slightly reduced dose. The primary risk to the fetus is maternal anaphylaxis, not the extract itself.

There is no evidence that allergenic proteins from Glechoma Hederacea Flowering Top pass into breast milk in significant quantities. Immunotherapy is generally considered safe for breastfeeding mothers, as the localized immune response does not interfere with lactation.

• Approved Age: Skin testing can be performed at any age, but it is most reliable in children over 2 years old.
• Immunotherapy: Usually reserved for children 5 years and older who can cooperate with the injection process and report symptoms of a reaction.
• Growth Effects: There are no known negative effects on growth or development associated with the use of allergenic extracts.

In patients over 65, the clinician must carefully evaluate cardiovascular health. The risk of using epinephrine to treat a reaction in an elderly patient with coronary artery disease must be weighed against the benefits of the allergy treatment. Additionally, skin reactivity decreases with age, which may lead to smaller wheal sizes during testing.

There are no specific restrictions for patients with renal impairment. However, clinicians should be aware that uremia (buildup of toxins in the blood) can sometimes cause generalized itching, which may make the interpretation of a skin test more difficult.

No dosage adjustments are required for patients with hepatic impairment. The liver does not play a major role in the processing of injected allergenic proteins.

> Important: Special populations require individualized medical assessment.

Glechoma Hederacea Flowering Top acts as a concentrated source of exogenous antigens. When these antigens are introduced into the skin of a sensitized individual, they cross-link IgE antibodies bound to the high-affinity receptor (FcεRI) on mast cells. This cross-linking triggers a signaling cascade involving tyrosine kinases, leading to the influx of calcium and the release of pre-formed mediators like histamine. In immunotherapy, the mechanism shifts toward immune tolerance by inducing IL-10 producing regulatory T cells and shifting the cytokine balance away from IL-4 and IL-5.

• Onset of Action: For diagnostic testing, the wheal and flare reaction begins within 5 minutes and peaks at 15–20 minutes.
• Duration of Effect: The immediate reaction subsides within a few hours, though a 'late-phase' reaction (swelling and redness) can occur 4–8 hours later.
• Tolerance: In immunotherapy, clinical tolerance (reduction in symptoms) typically takes 6–12 months of consistent treatment to manifest.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | Primarily to IgE and IgG4 |

| Half-life | Proteins degraded within 24-48 hours |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Proteolysis by local proteases |

| Excretion | Not renally excreted as intact proteins |

The extract is a complex mixture of proteins, glycoproteins, and polysaccharides. It contains various secondary metabolites characteristic of the Lamiaceae family, including rosmarinic acid and various terpenes, although the allergenic potential is primarily attributed to the protein fraction. It is soluble in aqueous buffers and stable in 50% glycerin solutions.

Glechoma Hederacea Flowering Top is classified as a Non-Standardized Plant Allergenic Extract. It shares this classification with other weed and herb extracts like Dandelion, Nettle, and Sage extracts.